Augmenix is focused on improving the outcomes of cancer treatment through the use of innovative hydrogels. Our technology is designed to minimize unintended radiation damage to normal organs and the accompanying side effects. Our mission is to provide cancer patients with a greater potential for maintaining their long-term Quality of Life.
Developing Advanced Hydrogel Products for Radiotherapy
Started in 2007, Augmenix is focused on improving the outcomes of radiotherapy through the use of absorbable hydrogels. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during radiation therapy and to mark soft tissue.
“On October 16, 2018, Boston Scientific Corporation (NYSE: BSX) announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The biodegradable SpaceOAR hydrogel is injected between the rectum and prostate to decrease a patient’s exposure to rectal radiation and thereby reduce rectal radiation injury – one of the most common complications of prostate radiotherapy.” Read more here
SpaceOAR Hydrogel was FDA Cleared on April 1, 2015.
TraceIT® Tissue Marker
More recently Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT® Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking.
This technology licensed from Incept LLC comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix now intends to bring this technology to the field of medicine through an experienced management team and high quality investors.
TraceIT Tissue Marker was FDA Cleared on January 23, 2013.